![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Efficacy and Safety of Switching to Dolutegravir/Lamivudine by Baseline Regimen
in Virologically Suppressed Adults: 48-Week Pooled Analysis
|
|
|
AIDS 2022 July 29-Aug 1 Montreal
Stefan Scholten,1 Pedro Cahn,2 Peter Ruane,3 Richard Kaplan,4 Joaquín Portilla,5 Sally Hodder,6 Fiona Bisshop,7 Brian R. Wynne,8 Richard Grove,9 Gilda Bontempo,8
Riya Moodley,10 Bryn Jones,10 Mounir Ait-Khaled,10 Chinyere Okoli10
1Praxis Hohenstaufenring, Cologne, Germany; 2Fundación Huésped, Buenos Aires, Argentina; 3Ruane Clinical Research, Los Angeles, CA, USA; 4Desmond Tutu Health Foundation, Cape Town, South Africa;
5Hospital General Universitario de Alicante, Alicante, Spain; 6School of Medicine, West Virginia University, Morgantown, WV, USA; 7Holdsworth House Medical Brisbane, Queensland, Australia; 8ViiV Healthcare,
Durham, NC, USA; 9GSK, Brentford, UK; 10ViiV Healthcare, Brentfor, UK
![0804221copy](../images/080522/080522-13/0804221copy.gif)
![0804222copy](../images/080522/080522-13/0804222copy.gif)
![0804223copy](../images/080522/080522-13/0804223copy.gif)
![0804224copy](../images/080522/080522-13/0804224copy.gif)
![0804225copy](../images/080522/080522-13/0804225copy.gif)
![0804226copy](../images/080522/080522-13/0804226copy.gif)
![0804227copy](../images/080522/080522-13/0804227copy.gif)
![0804228copy](../images/080522/080522-13/0804228copy.gif)
![0804229copy](../images/080522/080522-13/0804229copy.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|